surmount-1 tirzepatide non-diabetic obesity trial (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Effect of tirzepatide in SURMOUNT-1
Pay in 4 interest-free payments of $7.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29

01200-X/asset/a888810c-3ccf-4f48-b252-0dfdf720d276/main.assets/gr3_lrg.jpg)















![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)




